Valuation: Outlook Therapeutics, Inc.

Market Cap 207M 181M 167M 156M 293M 19.5B 299M 2.01B 777M 9.64B 776M 759M 33.41B P/E 2026 *
-3.29x
P/E 2027 * -6.49x
Enterprise Value 207M 181M 167M 156M 293M 19.5B 299M 2.01B 777M 9.64B 776M 759M 33.41B EV / Sales 2026 *
172x
EV / Sales 2027 * 4.52x
Free-Float
82.58%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Outlook Therapeutics, Inc.

1 day+6.21%
1 week+8.23%
Current month+134.25%
1 month+131.08%
3 months+721.72%
6 months-6.04%
Current year+8.23%
1 week 1.53
Extreme 1.5302
1.87
1 month 0.68
Extreme 0.6752
1.88
Current year 0.16
Extreme 0.1611
1.88
1 year 0.16
Extreme 0.1611
3.39
3 years 0.16
Extreme 0.1611
37
5 years 0.16
Extreme 0.1611
65.4
10 years 0.16
Extreme 0.1611
878.4
Manager TitleAgeSince
Chief Executive Officer 54 01/07/2025
Chief Executive Officer 60 03/12/2024
Chief Tech/Sci/R&D Officer - 19/01/2023
Director TitleAgeSince
Director/Board Member 60 02/08/2018
Director/Board Member 65 11/12/2015
Chairman 41 31/01/2025
Date Insider Type Main position Quantity % Market Cap.
06-02Buy

Director

29,000 0.0181%
05-28
Gms Ventures & Investments
BuyCompany 39,516,849 24.6751%
05-27Buy

Chairman

122,174 0.1471%
Change 5-day change 1-year change 3-year change Capi.($)
+6.21%+8.23%+6.88%-94.86% 207M
+0.86%+7.75%-4.57%+3.10% 46.2B
+2.19%+11.71%+393.31%+580.42% 38.71B
+2.53%+13.93%+21.38%-12.81% 31.9B
+1.65%+3.61%+16.04%+55.62% 31.12B
-4.16%-2.58%+8.94%+25.31% 23.77B
-0.32%+12.96% - - 16.2B
+1.37%+14.53%+69.64%+130.07% 15.05B
-0.44%+8.19%+13.63%+21.56% 13.74B
+3.63%+9.53%+103.97%+98.73% 13.42B
Average +1.35%+9.05%+69.91%+89.68% 23.03B
Weighted average by Cap. +0.94%+8.71%+88.92%+131.21%

Financials

2026 *2027 *
Net sales 1.2M 1.05M 970K 908K 1.7M 113M 1.74M 11.66M 4.51M 55.95M 4.51M 4.41M 194M 45.73M 40.09M 36.96M 34.6M 64.88M 4.31B 66.23M 444M 172M 2.13B 172M 168M 7.39B
Net income -53.44M -46.85M -43.19M -40.43M -75.82M -5.04B -77.39M -519M -201M -2.49B -201M -196M -8.64B -35.55M -31.17M -28.73M -26.9M -50.44M -3.35B -51.48M -345M -134M -1.66B -133M -131M -5.75B
Net Debt - -
Logo Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.
Employees
17
Date Price Change Volume
26/06/26 $1.710 +6.21% 11,491,945
25/06/26 $1.610 -4.17% 9,147,785
24/06/26 $1.680 -1.18% 8,676,520
23/06/26 $1.700 -7.10% 10,792,078
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
1.710USD
Average target price
5.500USD
Spread / Average Target
+221.64%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OTLK Stock